captopril has been researched along with pravastatin in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (29.17) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 9 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Conway, EL; Howes, LG; Krum, H; Lam, W; Louis, WJ; O'Callaghan, CJ; Skiba, MA | 2 |
| Darioli, R; Greminger, P; Riesen, W; Simeon-Dubach, D; Waeber, B; Wunderlin, R | 1 |
| Arsenescu, I; Provendier, O; Witchitz, S | 1 |
| Aberg, G; Beyer, S; Durham, S; Goller, N; Kowala, MC; Recce, R; Valentine, M | 1 |
| Albarrán, OG; García-Robles, R; Rábano, A; Ruilope, LM; Villa, E | 1 |
| Foss, OP; Graff-Iversen, S; Graving, B; Istad, H; Søyland, E; Tjeldflaat, L | 1 |
| Huang, Z; Jansson, L; Sjöholm, A | 3 |
2 review(s) available for captopril and pravastatin
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for captopril and pravastatin
| Article | Year |
|---|---|
Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients.
Topics: Blood Pressure; Captopril; Cholesterol; Cholesterol, LDL; Combined Modality Therapy; Double-Blind Method; Drug Interactions; Felodipine; Female; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Middle Aged; Pravastatin | 1994 |
Efficacy of pravastatin in combination with captopril in hypertensive patients.
Topics: Adult; Aged; Analysis of Variance; Captopril; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Humans; Hypercholesterolemia; Hypertension; Middle Aged; Pravastatin; Treatment Outcome | 1995 |
Combined treatment with captopril, hydrochlorothiazide and pravastatin in dyslipidemic hypertensive patients.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Captopril; Combined Modality Therapy; Diuretics; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pravastatin; Prospective Studies; Sodium Chloride Symporter Inhibitors | 1995 |
[Comparative effects of captopril and atenolol on lipid metabolism in hypertensive hypercholesterolemic patients treated with pravastatin. A multicenter controlled trial].
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Captopril; Double-Blind Method; Female; Humans; Hypercholesterolemia; Hypertension; Lipid Metabolism; Male; Middle Aged; Pravastatin; Time Factors | 1996 |
Treatment of hypertensive and hypercholesterolaemic patients in general practice. The effect of captopril, atenolol and pravastatin combined with life style intervention.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atenolol; Captopril; Combined Modality Therapy; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hypertension; Life Style; Male; Middle Aged; Norway; Pravastatin; Statistics, Nonparametric | 1999 |
17 other study(ies) available for captopril and pravastatin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril: ACE in atheromas provides cellular targets for captopril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anticholesteremic Agents; Arteriosclerosis; Blood Pressure; Captopril; Cholesterol; Cricetinae; Immunohistochemistry; Lipids; Lipoproteins; Male; Mesocricetus; Peptidyl-Dipeptidase A; Pravastatin; RNA, Messenger | 1998 |
Effects of chronic combined treatment with captopril and pravastatin on the progression of insulin resistance and cardiovascular alterations in an experimental model of obesity in dogs.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Captopril; Cardiovascular Diseases; Cholesterol; Coronary Vessels; Disease Models, Animal; Disease Progression; Dogs; Drug Therapy, Combination; Heart; Insulin; Insulin Resistance; Linear Models; Male; Multivariate Analysis; Myocardium; Obesity; Pravastatin; Triglycerides | 1998 |
Pancreatic islet blood flow is selectively enhanced by captopril, irbesartan and pravastatin, and suppressed by palmitate.
Topics: Adrenal Glands; Animals; Biphenyl Compounds; Blood Glucose; Blood Pressure; Captopril; Insulin; Irbesartan; Islets of Langerhans; Kidney; Male; Palmitic Acid; Pancreas; Pravastatin; Rats; Rats, Wistar; Regional Blood Flow; Tetrazoles | 2006 |
Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Glucose; Captopril; Diabetes Mellitus, Type 2; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Irbesartan; Islets of Langerhans; Pancreas; Pravastatin; Rats; Rats, Wistar; Regional Blood Flow; Sex Factors; Tetrazoles; Vasodilator Agents | 2007 |
Gender-specific regulation of pancreatic islet blood flow, insulin levels and glycaemia in spontaneously diabetic Goto-Kakizaki rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Captopril; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Irbesartan; Islets of Langerhans; Male; Pravastatin; Rats; Rats, Mutant Strains; Regional Blood Flow; Sex Factors; Tetrazoles | 2008 |